Trials / Conditions / Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

9 registered clinical trials studyying Relapsed/Refractory Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy NCT06756321	Affiliated Hospital of Nantong University	EARLY_Phase 1
Recruiting	Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma NCT06532643	Shanghai First Song Biotechnology Co., LTD	EARLY_Phase 1
Completed	A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma NCT05713110	Hutchmed	Phase 2
Unknown	To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients NCT05400876	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1 / Phase 2
Unknown	Study of F527 in Patients With Relapsed or Refractory Lymphoma NCT05293028	Shandong New Time Pharmaceutical Co., LTD	Phase 1
Recruiting	Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma NCT05189093	Hangzhou Hanx Biopharmaceuticals, Ltd.	Phase 1 / Phase 2
Terminated	A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumo NCT05271279	Beijing Boren Hospital	EARLY_Phase 1
Completed	A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advan NCT02259010	Millennium Pharmaceuticals, Inc.	Phase 1
Completed	Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varyin NCT02214147	Millennium Pharmaceuticals, Inc.	Phase 1